Historically, diagnosis of AD has been primarily focused on clinical criteria4, but accumulating evidence has demonstrated that cerebrospinal fluid (CSF) biomarkers, including amyloid-β 42 (Aβ42) and tau (total tau (t-tau) and phosphorylated tau181 (p-tau181)) as well as positron emission tomography (PET)-amyloid and PET-tau, are reliable surrogate measures of neuropathologic change enabling more robust characterization of patients across the AD continuum5–7. Here, MAPT is linked to Alzheimer disease.